HC Wainwright Issues Pessimistic Estimate for ACTU Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Equities researchers at HC Wainwright dropped their FY2029 earnings per share estimates for Actuate Therapeutics in a research report issued to clients and investors on Wednesday, November 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.08 per share for the year, down from their prior estimate of $0.11. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Other analysts have also issued research reports about the company. B. Riley assumed coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Thursday, November 13th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Trading Down 3.4%

Shares of NASDAQ:ACTU traded down $0.20 on Thursday, reaching $5.65. The company had a trading volume of 14,043 shares, compared to its average volume of 66,880. The firm has a market capitalization of $131.31 million, a PE ratio of -6.50 and a beta of -0.23. Actuate Therapeutics has a 52-week low of $5.47 and a 52-week high of $11.99. The firm’s 50 day simple moving average is $6.86 and its 200-day simple moving average is $7.67.

Institutional Investors Weigh In On Actuate Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACTU. Goldman Sachs Group Inc. grew its position in shares of Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after purchasing an additional 11,105 shares in the last quarter. Voss Capital LP lifted its position in shares of Actuate Therapeutics by 157.7% during the 1st quarter. Voss Capital LP now owns 142,381 shares of the company’s stock worth $964,000 after purchasing an additional 87,135 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new position in shares of Actuate Therapeutics during the first quarter worth $70,000. Sfmg LLC acquired a new stake in shares of Actuate Therapeutics during the 1st quarter worth about $74,000. Finally, Gleason Group Inc. purchased a new stake in Actuate Therapeutics during the second quarter worth approximately $116,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.